Provided by Tiger Fintech (Singapore) Pte. Ltd.

Rhythm Pharmaceuticals Inc.

64.63
+1.923.06%
Post-market: 64.630.00000.00%17:52 EDT
Volume:1.09M
Turnover:69.90M
Market Cap:4.11B
PE:-14.90
High:65.53
Open:61.07
Low:60.00
Close:62.71
Loading ...

Rhythm Pharmaceuticals Gains FDA Approval for Expanded IMCIVREE Use

MT Newswires Live
·
21 Dec 2024

Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential

Benzinga
·
21 Dec 2024

Rhythm announces FDA approval of Imcivree for patients as young as 2

TIPRANKS
·
21 Dec 2024

BRIEF-Rhythm Pharmaceuticals Announces FDA Approval Of Imcivree(Setmelanotide) For Patients As Young As 2 Years Old

Reuters
·
21 Dec 2024

Rhythm Pharmaceuticals Announces FDA Approval of Imcivree® (Setmelanotide) for Patients as Young as 2 Years Old

THOMSON REUTERS
·
21 Dec 2024

Top Calls on Wall Street: FedEx, Nike, Affirm, BlackBerry, Merck, Oracle, Reddit, and More

The Fly
·
20 Dec 2024

Oppenheimer Initiates Coverage on Rhythm Pharmaceuticals With Outperform Rating, $76 Price Target

MT Newswires Live
·
20 Dec 2024

Rhythm Pharmaceuticals Is Maintained at Buy by Goldman Sachs

Dow Jones
·
06 Dec 2024

Rhythm Pharmaceuticals Price Target Maintained With a $69.00/Share by HC Wainwright & Co.

Dow Jones
·
04 Dec 2024

Nvidia Chipmaker Taiwan Semi Hits Buy Point Following Bullish Advance

Blockhead
·
03 Dec 2024

Rhythm Pharmaceuticals Says Imcivree Receives Expanded Marketing Authorization in UK

MT Newswires Live
·
03 Dec 2024

Rhythm Pharmaceuticals: MHRA expands marketing authorization for Imcivree

TIPRANKS
·
03 Dec 2024

Rhythm Pharmaceuticals Inc - Imcivree Expected to Be Available by Year-End Through Medicines for Children Program

THOMSON REUTERS
·
03 Dec 2024

Rhythm Pharmaceuticals Announces ▼ Imcivree® (Setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients With Bardet Biedl Syndrome or Pomc, Pcsk1, or Lepr Deficiency to Include Children as Young as 2 Years Old

THOMSON REUTERS
·
03 Dec 2024

Fintech Approaches Buy Point Of Extremely Rare Pattern Following 44% Burst

Blockhead
·
27 Nov 2024

Biotech Leader ADMA Hits New Buy Point After Recovering From Surprise Plunge

Blockhead
·
26 Nov 2024

Rhythm Pharmaceuticals Price Target Maintained With a $69.00/Share by HC Wainwright & Co.

Dow Jones
·
25 Nov 2024

Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level

Blockhead
·
19 Nov 2024

TD Cowen Sticks to Its Buy Rating for Rhythm Pharmaceuticals (RYTM)

TIPRANKS
·
19 Nov 2024

Rhythm Pharmaceuticals announces five presentations at ESPE 2024

TIPRANKS
·
18 Nov 2024